Virus News and Research

Latest Virus News and Research

Inovio commences immunization in U.S. Phase I clinical trial of SynCon H5N1 influenza DNA vaccine

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has immunized its first subject in a U.S. Phase I clinical trial to evaluate its SynCon™ H5N1 (avian) influenza DNA vaccine, VGX-3400X.

15 Jun 2010

Monoclonal antibodies induce long-lasting, protective antiviral immune response

Monoclonal antibodies are the largest class of biotherapeutic drugs. When administered to infected organisms to blunt the propagation of pathogenic viruses, they may also induce a long-lasting and protective antiviral immune response similar to that achieved by vaccination. These results obtained in mice by the "Oncogenèse et Immunothérapie" group at the Institut de Génétique Moléculaire de Montpellier (CNRS/Universités Montpellier 1 and 2), have been published on 10 June in PLoS Pathogens.

14 Jun 2010

ARCA receives approval to commence enrollment of first therapeutic trial using HIV vaccine candidate

News on the progress of a new trial may give new hope to patients with HIV who are dependent on anti-HIV drugs. The AIDS Research Consortium of Atlanta has received approval to begin enrollment of the first therapeutic trial ever conducted using a promising HIV vaccine candidate from Atlanta-based, GeoVax Inc, a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines.

14 Jun 2010

Genetic variation can predict how people infected with hepatitis C react to treatment: Scientists

A small genetic change can predict how people infected with hepatitis C react to treatment, paving the way to personalised therapy for this difficult to treat disease, the annual conference of the European Society of Human Genetics will hear today (Sunday 13 June). Dr. Zoltan Kutalik, from the Department of Medical Genetics, University of Lausanne, Switzerland, will tell delegates that individuals with this change, in a gene encoding for the antiviral cytokine (cell-signalling molecule) interferon lamda, reacts less well to treatment.

14 Jun 2010

AIDS/LifeCycle event raises $10M to support HIV/AIDS services

More than 2,400 participants in AIDS/LifeCycle arrived at the Veterans Center in Los Angeles today after traveling 545 miles from San Francisco over the past seven days in the world's largest annual HIV/AIDS fundraising event. In its ninth year, the event raised $10 million to support the services of San Francisco AIDS Foundation and the L.A. Gay & Lesbian Center that prevent new HIV infections and care for those living with HIV/AIDS.

14 Jun 2010

White blood cells with receptors for both virus and nerve proteins may assault nerves after fighting infection

A virus infection can incite the body to attack its own nerve tissue by activating unusual, disease-fighting cells with receptors for both viral and nerve proteins. The dual-receptor observation suggests a way brain and spinal cord nerve damage might be triggered in susceptible young adults afflicted with multiple sclerosis.

11 Jun 2010

Cubist to oppose Teva’s attempt to add new defense in patent infringement litigation

Cubist Pharmaceuticals, Inc. today announced that it will oppose a motion filed by the Teva defendants to amend their answer to add a new defense in the patent litigation between Cubist and Teva pending in the US District Court for the District of Delaware. A motion for leave to amend the answer is a request to be permitted to add a new allegation. The Teva defendants seek leave to amend their answer to allege that US Patent Nos. 6,468,967 and 6,852,689 are unenforceable due to inequitable conduct.

11 Jun 2010

Investment report on Novavax

MicroStockProfit.com announces an investment report featuring Novavax Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

11 Jun 2010

sanofi pasteur congratulates Canadian Public Health Association for 100 years of leadership and service

As a longstanding partner in Canada's public health system, sanofi pasteur congratulates the Canadian Public Health Association (CPHA) for their 100 years of leadership and service to our country's public health.

11 Jun 2010

NADHS organizes second annual Oral Cancer walk

For the second year, the Nashville Area Dental Hygienists' Society (NADHS) has organized a successful walk to promote oral cancer awareness for a disease that affects so many, yet so few know about. Hundreds of Nashville locals gathered for the "Boot Scootin' for Oral Cancer Screening II" event that recently took place at Nashville's Centennial Park to raise disease awareness, and funds for the Non-Profit Oral Cancer Foundation (OCF).

11 Jun 2010

Researchers to provide real-time analyses on potential disease threats during World Cup

Two Canadian researchers will be keeping a close eye on what hundreds of thousands of soccer fans take to the World Cup in South Africa _ and what they potentially bring home.

11 Jun 2010

New methodology may help control influenza

Scientists have uncovered the flu's secret formula for effectively evolving within and between host species: balance. The key lies with the flu's unique replication process, which has evolved to produce enough mutations for the virus to spread and adapt to its host environment, but not so many that unwanted genomic mutations lead to the flu's demise (catastrophic mutagenesis).

11 Jun 2010

PPMD to fund two promising research initiatives in Duchenne muscular dystrophy

Patricia A. Furlong, Founding President and CEO of Parent Project Muscular Dystrophy (PPMD), the largest non-profit organization in the United States focused on finding a cure for Duchenne muscular dystrophy (Duchenne), announced today that PPMD will be funding two critical, promising research initiatives in Duchenne.

11 Jun 2010

CPL Biologicals completes construction of vaccine facility in Dholka, India

CPL Biologicals (CPLB), a joint venture of Cadila Pharmaceuticals Ltd. and Novavax, Inc., today announced that it has completed construction of its vaccine facility in Dholka, India and will commence equipment and installation validation this month so that the facility conforms to global standards for production of vaccines for human use.

10 Jun 2010

Idenix initiates IDX320 proof-of-concept study for HCV infection

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it has initiated a 3-day proof-of-concept study of IDX320, a protease inhibitor for the treatment of hepatitis C virus (HCV) infection, under a Clinical Trial Application (CTA). The study is evaluating IDX320 in treatment-naive hepatitis C genotype 1-infected patients.

10 Jun 2010

Baylor Institute of Immunology Research receives nearly $35M as grants in 2009

Even in an economy that's proved devastating to charitable giving and government grants, the Baylor Institute of Immunology Research (BIIR), a component of Baylor Research Institute (BRI), has managed to buck the trend: BIIR received grants totaling nearly $35 million in 2009.

10 Jun 2010

New findings may help researchers design drugs that can prevent HIV

Researchers at the University of Iowa Carver College of Medicine and University of Nebraska Medical Center have created a three-dimensional picture of an important protein that is involved in how HIV -- the virus responsible for AIDS -- is produced inside human cells. The picture may help researchers design drugs that can prevent HIV from reproducing.

10 Jun 2010

SFDA approves China Medical Technologies' SPR-based HPV-DNA chip

China Medical Technologies, Inc., a leading China-based advanced in-vitro diagnostic company, today announced that it has received approval for its SPR-based HPV-DNA chip from the State Food and Drug Administration of China (the "SFDA").

10 Jun 2010

Interim results from PROPEL study of RG7128 submitted as abstract to AASLD for Annual Liver Meeting

Pharmasset, Inc. announced today that the interim results from the PROPEL study conducted by its partner Roche demonstrate that RG7128 triple combination therapy was safe and well tolerated. In that study, the safety profile of RG7128 (1000mg BID or 500mg BID), when administered for 8 or 12 weeks with Pegasys (peginterferon alfa-2a) and Copegus (ribavirin), the standard of care, was similar to the safety profile of SOC alone.

9 Jun 2010

Discovery Labs reports preliminary results from Surfaxin Phase 2 trial in children with Acute Respiratory Failure

Discovery Laboratories, Inc., reports preliminary results from its Phase 2 clinical trial of Surfaxin® in children with Acute Respiratory Failure (ARF), a critical condition often caused in children by severe respiratory infections. The objective of the study was to evaluate the safety and tolerability of intratracheal administration of Surfaxin and to assess whether Surfaxin treatment could decrease the duration of mechanical ventilation in children with ARF.

9 Jun 2010

Virus News and Research

Latest Virus News and Research

Inovio commences immunization in U.S. Phase I clinical trial of SynCon H5N1 influenza DNA vaccine

Monoclonal antibodies induce long-lasting, protective antiviral immune response

ARCA receives approval to commence enrollment of first therapeutic trial using HIV vaccine candidate

Genetic variation can predict how people infected with hepatitis C react to treatment: Scientists

AIDS/LifeCycle event raises $10M to support HIV/AIDS services

White blood cells with receptors for both virus and nerve proteins may assault nerves after fighting infection

Cubist to oppose Teva’s attempt to add new defense in patent infringement litigation

Investment report on Novavax

sanofi pasteur congratulates Canadian Public Health Association for 100 years of leadership and service

NADHS organizes second annual Oral Cancer walk

Researchers to provide real-time analyses on potential disease threats during World Cup

New methodology may help control influenza

PPMD to fund two promising research initiatives in Duchenne muscular dystrophy

CPL Biologicals completes construction of vaccine facility in Dholka, India

Idenix initiates IDX320 proof-of-concept study for HCV infection

Baylor Institute of Immunology Research receives nearly $35M as grants in 2009

New findings may help researchers design drugs that can prevent HIV

SFDA approves China Medical Technologies' SPR-based HPV-DNA chip

Interim results from PROPEL study of RG7128 submitted as abstract to AASLD for Annual Liver Meeting

Discovery Labs reports preliminary results from Surfaxin Phase 2 trial in children with Acute Respiratory Failure

A new way of characterising biomolecules eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in